New inhibitor could slow mesothelioma development

11 May 2017 by under Research/Treatment

587px Researcher looks through microscope 1 100x100 New inhibitor could slow mesothelioma developmentBecause cancer cells have high energy demands in order to replicate, new research has begun to target reducing cell energy levels as a way to fight cancer. In that vein of research, a new Japanese study has determined an orally available small molecule inhibitor can block tumor growth in colon and cancer cells.

According to Mesothelioma Research News, the researchers used inhibitor T-3764518 to block lipid biosynthesis, used by cancer cells to make energy. Specifically, the inhibitor blocks stearoyl-CoA desaturate-1 (SCD1), which is critical to the synthesis of fatty acid lipids into energy for a cell. SCD1 expression has been shown to accelerate the spread of other cancers, including of the breast and lungs, as many cancers are characterized by altered metabolism.

The study’s findings suggest SCD1 “might serve as a valid therapeutic target for a range of cancers,” according to the news source. In colon and mesothelioma cancer cells, the T-3764518 inhibitor was found to bind to SCD1 and prevent activity, eventually leading to a disruption of fatty acid composition that ended in cell death. When either colon cancer or mesothelioma cancer cells were implanted into mice and grew into tumors, treatment with “T-3764518 twice daily slowed tumor growth in a concentration-dependent manner — reducing tumor size in colon cancer by up to 42 percent, and up to 62 percent in the mesothelioma tumor model,” Mesothelioma Research News reports. As expected, it also altered the fatty acid composition of the mice’s tumor cells.

“These results indicate that T-3764518 is a promising new anticancer drug candidate,” the study concludes.


Comments are closed.